Survival Benefit of Pembrolizumab for Patients With Pancreatic Adenocarcinoma: A Case Series
Authors:
Open Access
- 1 May 2022
- journal article
- research article
- Published by Elmer Press, Inc. in Journal of Medical Cases
- Vol. 13 (5) , 240-243
Abstract
Survival Benefit of Pembrolizumab for Patients With Pancreatic Adenocarcinoma: A Case SeriesKeywords
This publication has 6 references indexed in Scilit:
- Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature ReviewJCO Precision Oncology, 2022
- Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectivesTherapeutic Advances in Medical Oncology, 2021
- Pancreatic cancer and immune checkpoint inhibitors—still a long way to goTranslational Gastroenterology and Hepatology, 2021
- Pancreatic cancerThe Lancet, 2020
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 StudyJournal of Clinical Oncology, 2020
- T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028Journal of Clinical Oncology, 2019